§ Mr. Meadowcroftasked the Secretary of State for Social Services how he intends to distinguish, in monitoring National Health Service drug costs and savings under limited list prescribing between cost reductions due to reduced return on capital for pharmaceutical companies and those due to the introduction of the limited list.
§ Mr. Kenneth ClarkeMonitoring of the volume and cost of prescriptions in the categories affected by the selected list and information from drug manufacturers will enable us to draw a distinction between savings in the drugs bill resulting from the introduction of selected list prescribing and those resulting from other measures.
§ Mr. Wilsonasked the Secretary of State for Social Services what is the estimated saving in National Health Service drug costs which will ensue in a full year from the introduction of the limited list.
§ Mr. Kenneth Clarke£75 million.